CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Tuesday, Option Care Health (NASDAQ:OPCH), a healthcare services company with a market capitalization of $5.1 billion, maintained its Market Outperform rating and $36.00 price target from JMP analysts. The firm’s stance comes amid expectations of profit growth pressure in 2025 due to Stelara-related headwinds. JMP analysts project an adjusted EBITDA growth of 4% for the year, or an increase of 17-19% excluding Stelara’s impact. According to InvestingPro data, three analysts have recently revised their earnings estimates upward for the upcoming period, with price targets ranging from $35 to $41.
Analysts at JMP are closely monitoring Option Care Health’s strategic moves, especially its mergers and acquisitions pipeline, which could play a significant role in the company’s future growth. The competitive landscape within the industry, along with dynamics involving payors, are other key areas of focus for the analysts. The company has demonstrated strong execution, achieving 16.2% revenue growth in the last twelve months and maintaining healthy profitability metrics.
The utilization of infusion suites, a critical component of Option Care Health’s service offerings, is also under observation by JMP. Infusion suites are healthcare settings where patients receive intravenous therapy and are an integral part of the company’s business model. With an EBITDA of $385 million and a "GREAT" financial health score from InvestingPro, the company appears well-positioned to maintain its operational excellence.
Despite the anticipated challenges linked to Stelara, a medication used to treat various inflammatory conditions, Option Care Health’s overall growth prospects appear to remain positive in the eyes of JMP. The firm’s analysis suggests that, even with the Stelara headwinds, the company’s growth trajectory is expected to stay on course.
The $36.00 price target set by JMP indicates a level of confidence in Option Care Health’s ability to navigate the upcoming challenges while capitalizing on opportunities within the market. As the year progresses, investors and stakeholders will likely watch how the company adapts to the changing market conditions and leverages its strategic initiatives to maintain growth.
In other recent news, Option Care Health reported impressive financial results for the fourth quarter of 2024, surpassing earnings and revenue forecasts. The company achieved earnings per share of $0.44, exceeding the expected $0.35, and reported revenue of $1.35 billion, which was above the anticipated $1.27 billion. This performance marks a 19.7% increase in revenue year-over-year and a 15.8% rise in adjusted EPS. Analysts at Jefferies and Truist Securities have both raised their price targets for Option Care Health to $40, maintaining a Buy rating, reflecting confidence in the company’s strong outlook. The analysts cited robust free cash flow and strategic growth initiatives, including mergers and acquisitions, as key factors supporting their positive stance. Additionally, Option Care Health expanded its operations by opening new pharmacies and implementing advanced practitioner models, further solidifying its market position. With a $250 million stock repurchase, the company demonstrated its commitment to returning value to shareholders. These developments highlight the company’s strategic execution and potential for continued growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.